Overexpression of the EGFR is frequently identified in a variety of tumour entities, and several strategies have been developed to target EGFR in various tumours, including EGFR‐specific monoclonal antibodies (such as cetuximab) and tyrosine kinase inhibitors (such as erlotinib, which block the intracellular component of the receptor). Here, EGFR is linked to neoplasm.